Cargando…
Roflumilast Inhibits Lipopolysaccharide-Induced Tumor Necrosis Factor-α and Chemokine Production by Human Lung Parenchyma
BACKGROUND: Roflumilast is the first phosphodiesterase-4 (PDE4) inhibitor to have been approved for the treatment of COPD. The anti-inflammatory profile of PDE4 inhibitors has not yet been explored in human lung tissues. We investigated the effects of roflumilast and its active metabolite roflumilas...
Autores principales: | Buenestado, Amparo, Chaumais, Marie-Camille, Grassin-Delyle, Stanislas, Risse, Paul-André, Naline, Emmanuel, Longchampt, Elisabeth, Tenor, Hermann, Devillier, Philippe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3774805/ https://www.ncbi.nlm.nih.gov/pubmed/24066150 http://dx.doi.org/10.1371/journal.pone.0074640 |
Ejemplares similares
-
Clinical Relevance of the Anti-inflammatory Effects of Roflumilast on Human Bronchus: Potentiation by a Long-Acting Beta-2-Agonist
por: Salvator, Hélène, et al.
Publicado: (2020) -
The impact of low-frequency, low-force cyclic stretching of human bronchi on airway responsiveness
por: Le Guen, Morgan, et al.
Publicado: (2016) -
Expression and function of human hemokinin-1 in human and guinea pig airways
por: Grassin-Delyle, Stanislas, et al.
Publicado: (2010) -
Adiponectin Inhibits the Production of TNF-α, IL-6 and Chemokines by Human Lung Macrophages
por: Salvator, Hélène, et al.
Publicado: (2021) -
Effectiveness of a Load-Imposing Device for Cyclic Stretching of Isolated Human Bronchi: A Validation Study
por: Le Guen, Morgan, et al.
Publicado: (2015)